Literature DB >> 6137651

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.

T J McElwain, R L Powles.   

Abstract

1 previously untreated patient with plasma-cell leukaemia and 8 patients with myeloma (4 previously untreated) were treated with high-dose melphalan 100-140 mg/m2 iv. All responded to treatment. 3 of the 5 previously untreated patients achieved biochemical and bone-marrow complete remissions.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6137651     DOI： 10.1016/s0140-6736(83)90739-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  77 in total

Review 1.  [Role of high-dose chemotherapy in hematology and internal medicine/ oncology].

Authors:  A Engert; A Josting; M Reiser; D Söhngen; V Diehl
Journal:  Med Klin (Munich)       Date:  1999-08-15

Review 2.  Multiple myeloma.

Authors:  N Raje; K C Anderson
Journal:  Curr Treat Options Oncol       Date:  2000-04

Review 3.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

4.  Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.

Authors:  G Cook
Journal:  Bone Marrow Transplant       Date:  2015-08-03       Impact factor: 5.483

5.  High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

Authors:  Christa E Nath; Judith Trotman; Campbell Tiley; Peter Presgrave; Douglas Joshua; Ian Kerridge; Yiu Lam Kwan; Howard Gurney; Andrew J McLachlan; John W Earl; Ian Nivison-Smith; Lihua Zeng; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2016-04-27       Impact factor: 4.335

6.  DNA crosslinking damage and cancer - a tale of friend and foe.

Authors:  Yaling Huang; Lei Li
Journal:  Transl Cancer Res       Date:  2013-06       Impact factor: 1.241

Review 7.  Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?

Authors:  Hira S Mian; Tanya M Wildes
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

8.  Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy.

Authors:  M C Kuo; L Y Shih
Journal:  Ann Hematol       Date:  1995-09       Impact factor: 3.673

Review 9.  Recent developments in hematopoietic stem cell transplantation for multiple myeloma.

Authors:  William I Bensinger
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

10.  Impact of additional cytoreduction following autologous SCT in multiple myeloma.

Authors:  Sk Kumar; D Dingli; A Dispenzieri; Mq Lacy; S R Hayman; Fk Buadi; Sv Rajkumar; Mr Litzow; Ma Gertz
Journal:  Bone Marrow Transplant       Date:  2008-06-16       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.